LGR5 and graft versus host disease: Administration of recombinant human R-Spo1 protected Lgr5+ ISCs and Paneth cells against GVHD, resulting in maintenance of the integrity of the gut mucosa and intestinal commensals after murine allogeneic SCT4,9.